Teva announces favorable European Patent Office ruling in COPAXONE® patent proceeding
Posted: 28 May 2014 | | No comments yet
Teva Pharmaceutical Industries Ltd. announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party…
![TEVA LOGO](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/TEVA_LOGO.gif)
![TEVA LOGO](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/TEVA_LOGO.gif)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party. On September 6, 2012, the three opponents commenced an opposition proceeding against European Patent EP 2 177 528, a patent for COPAXONE® (glatiramer acetate injection) expiring September 9, 2025. In today’s hearing, the European Patent Office specifically determined that claims 1-12 of the ‘528 patent are valid. Therefore infringing follow-on glatiramer products would not be able to launch prior to patent expiry.
Teva will continue to vigorously defend its COPAXONE® intellectual property rights against infringement wherever they are challenged.